IMO: If tivo gains worldwide approval, it's a $20 stock at best [with the recent dilution]. If it fails EMA, it will be a temporary setback to the 50-70 cent levels for a couple years. If any of the other molecules come through - each adds a couple bucks.
Anyone know whether Aveo have a poison pill caveat - - that disallows a hostile buyout from a shareholder who accumulates majority of shares?
Parker, can you speak more to this huge carry forward loss, i.e. is it a consequence of them being in bed with Kirin et al?
Highlights: new section on AV-353 Notch 3 molecule for PAH, partnership discussions ongoing; EU Tivo approval now slated for 1Q17, Russia sooner in 3Q16; new slides for Tivo toxicity show adverse-effect superiority to several other competitor drugs.
I don't think the private placement shares actually dilute our public share pool, until the holders start selling into the open market.
Ok, that then would suggest NEA haven't decreased the public float by 30%, correct? And so while Harry Weller is the "activist investor" fingered here .. in this instance, he is simply a cog in the NEA wheel, who happen to own the GEO Fund.
Looking back at the 8-K they filed on 5/13, where it details the owners of the private placement's shares -- this Growth Equity Opportunities Fund is already named as acquiring 10,362,694 each of "Shares" and "Warrant Shares" -- for a grand total of 20,725,388.
This share count is the exact same value as the count provided yesterday in the 13D form, for reporting of common stock ownership.
So is this really new news? I find it hard to believe that they / NEA own the exact same 20+ million share count, in both private and public shares. Can anyone straighten me out?
rather paltry AH action though, wouldn't you agree. so is Weller really now holding 20 of 58 million public shares?